DeviceTalks Podcast Network

In this episode of the DeviceTalks Weekly Podcast, Managing Editor Kayleen Brown sits down with Johnson & Johnson MedTech Heart Recovery Worldwide President Devi Govender at DeviceTalks Boston.

Govender shares how a deeply personal family experience shaped her mission to transform cardiovascular care. She reflects on Abiomed's integration into Johnson & Johnson, the evolution of heart recovery therapies, and why the industry must shift its mindset from treating "heart failure" to enabling "heart recovery."

The discussion explores patient-centered innovation, AI, clinical evidence, and the power of combining technologies, data, and advocacy to redefine the future of cardiovascular care for patients around the world.

This episode is sponsored by  Freudenberg Medical. Listen for a conversation with Shane Healy, Senior Director of Technology. Visit FreudenbergMedical.com for more information.

We'll kick off this episode with Newmarker's Newsmakers. Host Tom Salemi and MassDevice Editor Chris Newmarker revisit the top MedTech stories of the week: Zeta Surgical, Hologic, Medtronic, Fractyl Health, and Vicarious Surgical.

---

Enjoy the show? Follow DeviceTalks Weekly on all major podcast platforms, and subscribe to YouTube.com/@DeviceTalks so you never miss an episode.

Want access to the complete DeviceTalks Podcast Network (DTPN)? Subscribe today at [https://devicetalks.castos.com/subscribe](https://devicetalks.castos.com/subscribe).

Chapters

(00:09:10) - Zeta wins FDA clearance for TMS robotic stereotactic system
(00:13:01) - Private equity firms reportedly set $4B price on Hologic Surgical unit
(00:15:03) - Medtronic, FDA pick up legal victories in spinal cord stimulator suits
(00:16:20) - Fractyl Health says its single-catheter treatment maintained most GLP-1 weight loss
(00:22:17) - Vicarious Surgical's board wants to shut down and liquidate the robotics developer
(00:29:53) - Interview with Shane Healy, Senior Director of Technology, Freudenberg Medical
(00:36:53) - Keynote interview with Devi Govender, Worldwide President, Heart Recovery, Johnson & Johnson MedTech

In this episode of DeviceTalks Weekly, Host Tom Salemi explores the breakthrough technologies—and the unique culture—driving one of MedTech's most ambitious missions with XCATH CEO Eduardo Fonseca. Fonseca shares the remarkable story behind XCATH's first remote robotic stroke procedure. Fonseca recounts the years of preparation, the high-stakes operation, and the emotional moment when a patient facing severe disability walked away with what he calls "a second birthday."

Along the way, Tom and Eduardo discuss AI's growing role in surgery, the global shortage of stroke specialists, the future of robotic intervention, and why expanding access—not simply advancing technology—is the company's ultimate goal.

To learn more about XCATH and talk with Fonseca, join us on July 29 for a live DeviceTalks discussion. Register here for the free webinar. Thank you to our sponsors Confluent, Jabil, Maxon, Solesis, Viant, and VitalPath.

MassDevice Editor Chris Newmarker returns to deliver this episode’s Newmarker’s Newsmakers – MDUFA, Corza Medical, Resmed, GTCR, Zimmer Biomet, Pacira Biosciences, and Johnson & Johnson MedTech.

 ***

Enjoy the show? Follow DeviceTalks Weekly on all major podcast players + Follow us on YouTube.com/@DeviceTalks to ensure you never miss an episode.

Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe

Chapters

(00:08:36) - FDA releases draft MDUFA VI agreement outlining proposed legislation and program changes
(00:12:50) - Resmed to sell MatrixCare software business to private equity firm for $490M/ GTCR to divest Biosurgery unit of Corza Medical
(00:15:58) - Medtronic’s chief sustainability officer is departing
(00:17:55) - Zimmer Biomet to pay up to $140M for Iovera nerve therapy tech from Pacira BioSciences
(00:19:56) - Johnson & Johnson wins FDA approval for ThermoCool SmartTouch dual-energy ablation system

In this episode of the DeviceTalks Weekly Podcast, host Tom Salemi is reassured by his conversation with Joe Catanese, CEO of Calyxo, a urology startup that has developed a system designed to simplify kidney stone removal.

Catanese previously helped build Neotract, a urology startup that was acquired by Teleflex for more than $1 billion. Now, he's leading another potential gamechanger and may have his sights set on an IPO.

Speaking of gamechangers, HistoSonics continues to shatter fundraising expectations. The company recently completed a financing round that valued it at $3.75 billion. In this week's FOMO interview, HistoSonics President and CEO Mike Blue speaks with MassDevice Editor Chris Newmarker during a keynote conversation at DeviceTalks Minnesota.

In this excerpt, Blue reflects on the company's first major fundraising round, which attracted high-profile investors including Jeff Bezos and Peter Thiel, and shares his perspective on just how large the opportunity for histotripsy could become.

But first, Tom and Jim Hammerand, managing editor of Medical Design & Outsourcing, discuss AI—or LLMs, or whatever term you prefer. Is the hype beginning to fade? And what should the industry make of the recent announcement from Midjourney Medical?

***

Enjoy the show? Follow DeviceTalks Weekly on all major podcast players + Follow us on YouTube.com/@DeviceTalks to ensure you never miss an episode.

Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe

Chapters

(00:05:29) - AI Talk with Jim Hammerand, managing editor, Medical Design & Outsourcing
(00:24:46) - DeviceTalks Minnesota interview excerpt - Mike Blue, CEO and President, Histosonics
(00:41:44) - Keynote Interview with Joe Catanese, CEO and President, Calyxo

In this episode of the DeviceTalks Weekly Podcast, Host Tom Salemi visits his MedTech happy place — renal denervation — with Recor Medical COO Helen Reeve Stoffer. Reeve Stoffer joined the company shortly before the bottom fell out of the renal denervation market in 2014. This interview picks up from that point and follows Recor's pursuit of FDA approval to where denervation technology may be applied next.

This week’s FOMO features a portion of a keynote interview with Manny Villafaña, MedTech legend and CEO of Medical 21. The conversation took place at DeviceTalks Minnesota and focuses on the dream that saved St. Jude Medical.

Skyler Rivera, associate editor of MassDevice, gives us a preview of her upcoming feature in Medical Design & Outsourcing magazine on the race to provide telesurgery capabilities to surgical robotic systems.

***

Enjoy the show? Follow DeviceTalks Weekly on all major podcast players + Follow us on YouTube.com/@DeviceTalks to ensure you never miss an episode.

Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe

Chapters

(00:02:42) - Associate Editor Skyler Rivera's path the MedTech (and MassDevice)
(00:06:00) - MDO covers the race for robotic telesurgery platforms in stroke
(00:11:12) - Rivera reviews the race leaders
(00:16:30) - FOMO Studio - Manny Villafana, MedTech Legend and CEO of Medical 21
(00:28:19) - Keynote Interview - Helen Reeve Stoffer, COO, Recor Medical

In this episode, Host Tom Salemi is joined by Darla Hutton, Intuitive’s global vice president of cardiac surgery, to discuss the surgical robotics giant’s return to cardiac surgery.

Intuitive famously aimed for the heart at its outset but pivoted when cardiac surgery proved too complicated. Today, heart patients and surgeons are pushing for minimally invasive procedures, and Hutton, a former cardiac surgery OR nurse, has been tapped to lead the company’s push into an increasingly competitive specialty.

But first, Harmonic Drive’s Bill Frey, regional sales engineer, joins us in the FOMO Studio. Go to HarmonicDrive.net for more information.

Filling in for MassDevice’s Chris Newmarker, Senior Editor Sean Whooley wraps up the five biggest stories to come out of the American Diabetes Association meeting — Abbott, Senseonics, Sequel, Dexcom, and Insulet.

***

Enjoy the show? Follow DeviceTalks Weekly on all major podcast players + Follow us on YouTube.com/@DeviceTalks to ensure you never miss an episode.

Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe

Chapters

(00:04:43) - Abbott studies reinforce DKA opportunity following dual sensor milestone
(00:07:13) - Senseonics study supports Eversense 365 CGM with automated insulin delivery tech
(00:09:20) - Sequel Med Tech data supports twiist automated insulin delivery in type 2 diabetes
(00:11:18) - Dexcom study highlights benefits of G7 CGM in non-insulin type 2 diabetes
(00:13:01) - Insulet data backs Omnipod 6, fully closed-loop AID systems
(00:16:29) - FOMO Studio - Bill Frey, regional sales engineer, Harmonic Drive
(00:27:14) - Keynote Interview - Darla Hutton, Global Vice President, Cardiac Surgery Intuitive